Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 2
2020 9
2021 6
2022 10
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Targeting TAM to Tame Pancreatic Cancer.
von Itzstein MS, Burke MC, Brekken RA, Aguilera TA, Zeh HJ, Beg MS. von Itzstein MS, et al. Target Oncol. 2020 Oct;15(5):579-588. doi: 10.1007/s11523-020-00751-9. Target Oncol. 2020. PMID: 32996059 Free PMC article. Review.
T-cell tolerant fraction as a predictor of immune-related adverse events.
Ostmeyer J, Park JY, von Itzstein MS, Hsiehchen D, Fattah F, Gwin M, Catalan R, Khan S, Raj P, Wakeland EK, Xie Y, Gerber DE. Ostmeyer J, et al. Among authors: von itzstein ms. J Immunother Cancer. 2023 Aug;11(8):e006437. doi: 10.1136/jitc-2022-006437. J Immunother Cancer. 2023. PMID: 37580069 Free PMC article.
Strategies to maximize influenza vaccine impact in older adults.
Whitaker JA, von Itzstein MS, Poland GA. Whitaker JA, et al. Among authors: von itzstein ms. Vaccine. 2018 Sep 25;36(40):5940-5948. doi: 10.1016/j.vaccine.2018.08.040. Epub 2018 Aug 25. Vaccine. 2018. PMID: 30153995 Review.
How lung cancer cells change identity.
von Itzstein MS, Drapkin BJ, Minna JD. von Itzstein MS, et al. Elife. 2021 Aug 4;10:e71610. doi: 10.7554/eLife.71610. Elife. 2021. PMID: 34346867 Free PMC article.
Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D, Naqash AR, Espinoza M, Von Itzstein MS, Cortellini A, Ricciuti B, Owen DH, Laharwal M, Toi Y, Burke M, Xie Y, Gerber DE. Hsiehchen D, et al. Among authors: von itzstein ms. Oncoimmunology. 2022 Jan 5;11(1):2017162. doi: 10.1080/2162402X.2021.2017162. eCollection 2022. Oncoimmunology. 2022. PMID: 35003896 Free PMC article.
35 results